Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

This comparison between FBT (First Trust Nasdaq Biotech ETF) and XLV (Health Care Select Sector SPDR) highlights a classic risk-return trade-off within the health care sector. FBT's concentrated biotech exposure delivered superior absolute returns at 52.4% year-over-year, reflecting the sector's strong momentum in innovation-driven therapeutics and diagnostics. However, this outperformance came paired with elevated volatility and deeper drawdowns—a characteristic risk profile of smaller-cap, pipeline-dependent companies.

XLV's broader health care methodology incorporates large-cap diversification across pharmaceuticals, medical devices, insurers, and health care services, exemplified by holdings like JNJ and ABBV. This structural diversification reduces single-company idiosyncratic risk and provides lower expense ratios, making it more suitable for investors prioritizing capital preservation and steady income streams over growth velocity.

The performance differential reflects sector rotation dynamics: biotech indices benefit during growth-favoring rate environments and periods of elevated risk appetite, while defensive health care allocations stabilize during uncertainty. XLV's lower cost basis and rebalancing efficiency also provide compounding advantages over longer time horizons, offsetting FBT's recent outperformance.

Sector implication: This comparison underscores health care's dual nature—simultaneously offering defensive characteristics and high-beta growth exposure depending on portfolio construction. Macro factors including interest rates, FDA approval pipelines, and pharmaceutical pricing pressure remain critical drivers of relative performance between concentrated biotech and diversified health care allocations.